in the
.
Entos announces partnership with The Ottawa Hospital s Biotherapeutics Manufacturing Centre (BMC) to fill Covigenix VAX-001 in vials.
BMC and ACTM will collaborate to boost Canada s biotherapeutics manufacturing capacity.
EDMONTON, AB, Feb. 25, 2021 /CNW/ - Entos Pharmaceuticals (Entos), a biotechnology company developing genetic medicines with its Fusogenix nucleic acid delivery platform, is excited to work with Alberta Cell Therapy Manufacturing and The Ottawa Hospital s Biotherapeutics Manufacturing Centre to manufacture and ready doses of Entos made-in-Canada Covigenix VAX-001 vaccine for upcoming clinical trials at the Canadian Centre for Vaccinology.
Scientist working in the ACTM facility GMP cleanroom (CNW Group/Entos Pharmaceuticals)
Date Time
Share
CIHR and JDRF funding drives efforts to find new stem cell-based therapies for Type 1 diabetes
University of Alberta researchers are among two Canadian research teams chosen for significant new funding from the Government of Canada and JDRF Canada to develop new stem cell-based therapies for treating Type 1 diabetes.
The projects will each receive $1.5 million from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD) along with matching dollars from JDRF Canada, for total funding of $3 million per project over five years. The funding investment marks the anniversary of the Canadian discovery of insulin 100 years ago, a significant turning point in the work to defeat diabetes.